At 12 months, the OS rate for patients who received treatment with ipilimumab plus nivolumab was significantly superior to that for patients who received the current SOC.
Dr. McGregor explains the safety, efficacy, and subgroup analysis from ARC-20 in patients with previously treated ccRCC.
Dr. James showcases an MMAI model to identify benefit from 2nd-generation ARPIs in hr/nm PCa patients from STAMPEDE.
Avelumab plus sacituzumab govitecan may improve PFS in patients with advanced bladder cancer.
Dr. Jorge Garcia joins the podcast to discuss the process of selecting abstracts for oral presentation and select highlights from this session.
Dr. Toni Choueiri discusses this combination cohort of HIF inhibition plus VEGF-R inhibition.
Vitaly Margulis, MD, UT Southwestern Medical Center, walks through the ENLIGHTED trial interim analysis.
Dr. Braun details an integrative analysis of the Checkmate 9ER trial that highlights both circulating and TME biomarkers.
Drs. Necchi and Tawagi break down in detail the first results of SURE-02 in patients with muscle-invasive bladder cancer.
The FDA recently approved UroGen’s mitomycin and hydrogel formulation (Zusduri) for potent tumor ablation in patients with recurrent low-grade, intermediate-risk NMIBC.
Drs. Privé and Tagawa discuss the BULLSEYE trial, an analysis of Lutetium-177-PSMA-617 in oligometastatic HSPC.
